Skip to NavigationSkip to content

Johnson & Johnson

J&J must pay $572 million for fuelling opioid crisis in Oklahoma, judge says

A judge in Oklahoma has said that Johnson & Johnson must pay $572 million for the part it played in fuelling the opioid crisis which kills more than 130 a day in the United States.

Cleveland County District Judge Thad Balkman has said Johnson & Johnson must pay the state of Oklahoma $572,102,028, after Oklahoma prosecutors demanded more than $17 billion in payment over the role the firm played in worsening the opioid crisis through aggressively marketing opioid drugs.

J&J's ponesimod meets primary and secondary endpoints at Phase 3 in relapsing multiple sclerosis

New Phase 3 data has been released on Johnson & Johnson’s selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod, reporting that the drug performed favourably compared to Genzyme’s Aubagio (teriflunomide) in the treatment of adult patients with relapsing multiple sclerosis.

J&J 'worse' than Purdue Pharma expert witness says

The role Johnson & Johnson played in the opioid crisis was ‘in some ways worse’ than that of Purdue Pharma, an expert witness said in the Oklahoma trial of J&J.

Dr Andrew Kolodny, the co-director of the Opioid Policy Research Collaborative at Brandeis University, has said that healthcare conglomerate J&J may have played a bigger role in the opioid crisis than the Sackler owned firm Purdue Pharma.

Janssen closes plant in California, 49 positions axed

Janssen are letting go of 49 employees due to the closure of their plant in Vacaville, California.

The Johnson & Johnson subsidiary took over the plant in 2001, after the healthcare conglomerate acquired the Palo Alto-based ALZA Corporation for $10.5 billion.

However the permanent closure will see 49 workers lose their jobs, as Janssen announced their decision to close the Vacaville facility. The firm said that the plant was no longer needed due to a shift in focus towards other areas.

Indian authorities say J&J's baby shampoo contains 'harmful ingredients'

Indian authorities in the state of Rajasthan have said that samples taken from Johnson & Johnson’s baby shampoo contained ‘harmful ingredients.’

The Rajasthan Drugs Control Organisation's said in a notice date 5 March, that samples of J&J’s baby shampoo had failed quality tests. The US healthcare conglomerate rejected the claims.

J&J bows to PETA pressure and drops forced swim tests in mice

Johnson & Johnson has announced it is to end its practice of forced swim tests on mice, rats and other animals in the research of new drug treatments, following discussion with animal rights advocacy group PETA. The company’s pledge means it will not use the test from now on in either its own or external laboratories.

Forced swimming tests – or behavioural despair tests, as they are also known – involve placing a mouse or rat in an acrylic cylinder from which they cannot escape as it slowly fills with water.

J&J to include prices in drug ads on TV

US multinational Johnson & Johnson has announced that it will include the price of its medicines in TV commercials for its drugs.

The world’s largest healthcare company will become the first to take action after President Trump called on pharma firms to include prices in adverts of drugs on TV.

The healthcare conglomerate will include both the list price of the products being advertised as well as the out-of-pocket costs the consumer should expect to pay.

J&J shares plummet after asbestos cover up allegations emerge

Shares in American healthcare firm Johnson & Johnson plummeted on Friday after news agency Reuters reported that the New Jersey-based multinational had known its talcum powders had been contaminated with asbestos since the 1970s.

In reviewing documents made public by courts, Reuter’s investigators found that J&J had been aware that their baby powders were contaminated with trace amounts of asbestos since at least 1971.

NHS scraps restriction on availability of J&J's Imbruvica in leukaemia patients

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), expanding its use to cover treatment-naïve patients with chronic lymphoblastic forms of the condition (CLL).

The drug was originally approved in January last year as a treatment for CLL in patients whose cancer had returned following chemotherapy, but despite a recommendation of its efficacy from NICE, NHS England reportedly skirted clinical professionals to restrict its use to only those who had relapsed in the last t

J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy of its SGLT2 inhibitor Invokana (canagliflozin), but not because it had proved ineffective.

On the contrary, after the drug met its pre-specified efficacy criteria in the prevention of clinically important renal and cardiovadcvular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), the company deemed it pertinent to close the study early.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches